

Review Article

Anemia in Pregnancy: The Role of Red Cell Indices in Diagnosis and Monitoring

Emmanuel Ifeanyi Obeagu*

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe

***Corresponding author:** Emmanuel Ifeanyi Obeagu¹Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.

Email: emmanuelobeagu@yahoo.com

Received: November 14, 2024; **Accepted:** December 05, 2024; **Published:** December 12, 2024**Abstract**

Anemia in pregnancy is a widespread health issue affecting millions of women globally, with significant implications for both maternal and fetal outcomes. This condition, characterized by low hemoglobin levels, can lead to complications such as preterm birth, low birth weight, and increased maternal mortality. Early diagnosis and effective management are essential to mitigate these risks. Among the most valuable tools for identifying and monitoring anemia are red cell indices—parameters that include Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), and Mean Corpuscular Hemoglobin Concentration (MCHC). These indices provide insights into the size, hemoglobin content, and concentration in red blood cells, enabling clinicians to differentiate types of anemia and establish an appropriate management plan for pregnant women. Each type of anemia presents unique red cell indices patterns. For instance, iron deficiency anemia, the most common form in pregnancy, is typically identified by low MCV and MCH, indicating microcytic and hypochromic red blood cells. In contrast, megaloblastic anemia, often due to folate or vitamin B12 deficiencies, presents with elevated MCV, showing macrocytic RBCs. Through careful analysis of these indices, clinicians can tailor treatment to the underlying cause of anemia, whether through iron supplementation, folate, or vitamin B12, thus optimizing maternal health and reducing potential risks to the fetus.

Keywords: Anemia in pregnancy; Red cell indices; Hemoglobin; Maternal health; Diagnostic markers

Introduction

Anemia in pregnancy is a significant global health concern, particularly in low- and middle-income countries where nutritional deficiencies, infections, and limited healthcare resources contribute to its high prevalence. Defined by reduced hemoglobin levels, anemia in pregnancy affects oxygen delivery to tissues, leading to a range of adverse health outcomes for both the mother and the fetus. The World Health Organization (WHO) estimates that approximately 40% of pregnant women worldwide are anemic, with a higher concentration in developing countries. This widespread prevalence highlights the importance of effective diagnostic and monitoring strategies to manage anemia and reduce associated risks, such as preterm birth, low birth weight, and maternal mortality [1]. The physiological changes during pregnancy make it a unique context for anemia management. Blood volume expands by nearly 50% to meet the increased demands of the growing fetus and the placenta, which can result in hemodilution and a relative decrease in hemoglobin concentration, a condition known as physiological anemia of pregnancy. However, this normal decrease in hemoglobin can mask underlying iron deficiency or other types of anemia, underscoring the need for specific diagnostic tools to distinguish between physiological changes and true anemia. Without accurate diagnosis and timely intervention, anemia during pregnancy can progress, leading to more severe complications [2]. Red cell indices, a set of parameters obtained through a Complete Blood Count (CBC), are valuable tools in diagnosing and characterizing anemia.

These indices include Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC), and Red cell Distribution Width (RDW). Each index provides information about different aspects of red blood cells, such as their size, hemoglobin content, and uniformity. By analyzing these indices, healthcare providers can determine the type and likely cause of anemia, which is critical for tailoring treatment. For example, a low MCV suggests iron deficiency anemia, while a high MCV is more indicative of vitamin B12 or folate deficiency anemia [3]. Iron Deficiency Anemia (IDA) is the most common form of anemia during pregnancy and is typically characterized by microcytic (small-sized) and hypochromic (low-hemoglobin) red blood cells. This type of anemia often results from insufficient iron intake or increased iron demands that are not met, which is particularly common in pregnant women due to the additional iron requirements for fetal development. In addition to IDA, pregnant women may also experience megaloblastic anemia, usually caused by folate or vitamin B12 deficiency, which results in macrocytic red blood cells. Hemolytic anemia, either hereditary or acquired, can also occur and is characterized by normocytic or slightly macrocytic RBCs with increased RBC destruction [4]. The role of red cell indices goes beyond simply diagnosing the type of anemia; these indices are also crucial in monitoring the effectiveness of treatment interventions over time. By regularly assessing MCV, MCH, MCHC, and hemoglobin

levels, healthcare providers can track how well a patient is responding to iron, folate, or vitamin B12 supplementation and adjust treatment as necessary. This ongoing assessment is particularly important in pregnancy, where rapid changes can occur, and timely adjustments are essential for optimal maternal and fetal health outcomes. For instance, a stable or rising hemoglobin level along with normalized MCV and MCH may indicate a positive response to iron therapy in cases of iron deficiency anemia [5]. Furthermore, red cell indices are valuable in resource-limited settings where access to more advanced diagnostic tools may be restricted. In such contexts, red cell indices, which are part of routine CBC tests, offer a cost-effective way to diagnose and manage anemia without requiring complex equipment or tests. Their ability to help differentiate anemia types can significantly enhance the quality of prenatal care, particularly in areas with high anemia prevalence. Integrating red cell indices into standard prenatal screenings can therefore improve the early detection of anemia, enabling healthcare providers to implement timely and targeted interventions that minimize health risks for both mother and child [6].

Types of Anemia in Pregnancy

Anemia in pregnancy encompasses various forms, each with distinct causes, clinical presentations, and implications for maternal and fetal health. Understanding these types is crucial for accurate diagnosis, effective treatment, and prevention of potential complications. The most common types include iron deficiency anemia, megaloblastic anemia, and hemolytic anemia, each of which impacts pregnant women in unique ways.

1. Iron Deficiency Anemia (IDA): Iron deficiency anemia is the most prevalent type of anemia during pregnancy, largely due to increased iron demands that arise as a result of expanded blood volume, fetal development, and placental growth. Characterized by microcytic (small-sized) and hypochromic (pale) red blood cells, IDA results from insufficient iron intake or stores to meet these increased demands. Pregnant women with IDA may experience symptoms such as fatigue, weakness, and shortness of breath, which can escalate if untreated. Additionally, severe IDA increases the risk of preterm birth, low birth weight, and compromised maternal health. Diagnosis is typically made based on low hemoglobin levels, Mean Corpuscular Volume (MCV), and serum ferritin levels, which reflect depleted iron stores [7].

2. Megaloblastic Anemia: Megaloblastic anemia, often due to folate or vitamin B12 deficiencies, is another form that can impact pregnant women, especially those with dietary deficiencies or absorption issues. This type of anemia is characterized by macrocytic (large-sized) red blood cells, which result from impaired DNA synthesis that affects cell division and maturation. Folate deficiency is particularly common during pregnancy because of increased fetal requirements and the role of folate in cell division and growth. Without adequate folate, there is an increased risk of neural tube defects in the fetus. Vitamin B12 deficiency, though less common, can also lead to megaloblastic anemia and is often associated with strict vegetarian or vegan diets without supplementation. Diagnosis relies on elevated MCV, low hemoglobin, and low serum folate or vitamin B12 levels [8].

3. Hemolytic Anemia: Hemolytic anemia in pregnancy can either be inherited (such as sickle cell disease or thalassemia) or acquired, and it occurs when red blood cells are destroyed faster than they can be replaced. Hemolytic anemias are typically normocytic (normal-sized RBCs) or macrocytic, depending on the underlying cause. Inherited forms, like sickle cell disease, can exacerbate pregnancy complications, including pain crises, preeclampsia, and increased risk of maternal and fetal morbidity. Acquired hemolytic anemia may arise from autoimmune conditions, infections, or certain medications. Diagnosis involves examining reticulocyte counts, bilirubin levels, and specific tests for hemolysis markers such as Lactate Dehydrogenase (LDH) and direct Antiglobulin Tests (DAT) in cases of autoimmune hemolytic anemia [9].

4. Anemia of Chronic Disease (ACD): Anemia of chronic disease is a less common type during pregnancy but can occur in women with underlying chronic inflammatory or infectious conditions, such as tuberculosis, HIV, or autoimmune disorders. ACD is typically normocytic and normochromic, meaning RBC size and color remain within normal ranges, but hemoglobin levels are low due to impaired erythropoiesis and altered iron metabolism. The inflammatory cytokines associated with chronic disease reduce iron availability and inhibit erythropoiesis, making ACD challenging to manage in pregnancy. Diagnosis is usually based on low hemoglobin levels alongside normal or increased ferritin levels, reflecting retained iron stores but with limited bioavailability [10].

5. Aplastic Anemia: Although rare, aplastic anemia can be life-threatening during pregnancy. This condition results from bone marrow failure, leading to a decreased production of all blood cell types, including RBCs, white blood cells, and platelets. Aplastic anemia in pregnancy may be caused by autoimmune reactions, viral infections, or exposure to certain medications or toxins. Symptoms include severe fatigue, increased susceptibility to infections, and bleeding complications, making it a critical condition to manage. Diagnosis requires bone marrow biopsy, which reveals hypocellular bone marrow with decreased hematopoietic cells. Treatment may involve blood transfusions and immunosuppressive therapy, but management during pregnancy is complex and requires specialized care [11].

Red Cell Indices and Their Importance in Anemia Diagnosis

Red cell indices are fundamental parameters in evaluating the characteristics of Red Blood Cells (RBCs) and play a pivotal role in diagnosing, classifying, and monitoring anemia. Derived from a Complete Blood Count (CBC), these indices include Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC), and Red cell Distribution Width (RDW). Each of these indices provides specific insights into RBC size, hemoglobin content, and distribution, helping clinicians differentiate between types of anemia and identify potential underlying causes. Proper interpretation of these indices is essential for effective anemia management, particularly in pregnancy where early diagnosis can prevent adverse outcomes [12].

1. Mean Corpuscular Volume (MCV): MCV measures the average size of RBCs and is a critical index for classifying anemia. It helps distinguish between microcytic (small-sized RBCs), normocytic

(normal-sized RBCs), and macrocytic (large-sized RBCs) anemia. For instance, a low MCV (microcytic) typically indicates iron deficiency anemia, the most common type in pregnancy. Conversely, a high MCV (macrocytic) suggests megaloblastic anemia, often due to folate or vitamin B12 deficiencies. Normal MCV values (normocytic) in anemia may indicate hemolytic anemia or anemia of chronic disease. By categorizing RBC size, MCV allows clinicians to narrow down the potential causes of anemia and guide specific treatment strategies [13].

2. Mean Corpuscular Hemoglobin (MCH): MCH represents the average amount of hemoglobin per RBC and reflects the cell's hemoglobin content, which contributes to its color. MCH values are typically lower in hypochromic anemias, such as iron deficiency anemia, where RBCs have less hemoglobin and appear paler. In contrast, macrocytic anemias, such as those caused by folate or B12 deficiencies, often show elevated MCH due to the increased hemoglobin content in larger cells. By measuring hemoglobin per cell, MCH helps distinguish between hypochromic and normochromic anemia types, offering further insights into the nature of the deficiency and guiding dietary or supplemental interventions [14].

3. Mean Corpuscular Hemoglobin Concentration (MCHC): MCHC calculates the average concentration of hemoglobin in a given volume of RBCs, providing information on the color and density of hemoglobin within cells. Low MCHC levels indicate hypochromic anemia, where RBCs have insufficient hemoglobin concentration, which is characteristic of iron deficiency anemia. Normal MCHC values are often seen in normochromic anemias, such as those associated with chronic diseases or hemolytic anemia. MCHC is especially useful in differentiating types of microcytic anemia and, along with MCV and MCH, provides a comprehensive view of hemoglobin distribution across RBCs, helping clinicians identify anemia types more accurately [15].

4. Red Cell Distribution Width (RDW): RDW measures the variability in RBC size, indicating the degree of anisocytosis (variation in RBC size). An elevated RDW often signals a mixed anemia pattern or recent changes in erythropoiesis. For example, high RDW levels combined with low MCV are common in iron deficiency anemia, while high RDW and elevated MCV can suggest megaloblastic anemia. In pregnancy, where anemia may have multiple etiologies, RDW is particularly valuable in differentiating between iron deficiency and other types, helping refine diagnosis and treatment approaches.

Diagnostic Approach Using Red Cell Indices

A structured diagnostic approach using red cell indices allows clinicians to categorize anemia based on red blood cell characteristics and identify underlying causes. This method is particularly helpful in pregnancy, where early diagnosis and management are essential to minimize risks to both mother and fetus. The following step-by-step approach illustrates how each red cell index contributes to a comprehensive diagnostic pathway.

1. Starting with Hemoglobin Levels: The first step in diagnosing anemia involves measuring hemoglobin levels, as anemia is typically defined by hemoglobin below specific thresholds. During pregnancy, hemoglobin levels are often naturally lower due to blood volume expansion; however, values below 11 g/dL in the first and third trimesters and 10.5 g/dL in the second trimester usually indicate

anemia. Once anemia is confirmed, red cell indices are analyzed to classify the anemia type and pinpoint potential causes [16].

2. Assessing Mean Corpuscular Volume (MCV): MCV is crucial for the initial classification of anemia. An MCV below 80 fL suggests microcytic anemia, often linked to iron deficiency, the most common cause in pregnancy. An MCV above 100 fL indicates macrocytic anemia, frequently associated with folate or vitamin B12 deficiency. Normocytic anemia (MCV 80–100 fL) can suggest other causes, such as anemia of chronic disease or hemolytic anemia. By narrowing down the category (microcytic, normocytic, or macrocytic), MCV helps direct further testing and treatment strategies [17].

3. Evaluating Mean Corpuscular Hemoglobin (MCH) and Mean Corpuscular Hemoglobin Concentration (MCHC): MCH and MCHC provide additional insights into RBC hemoglobin content, helping to confirm and further refine the anemia classification. In cases of microcytic anemia, low MCH and MCHC values (hypochromic anemia) reinforce the likelihood of iron deficiency anemia, where RBCs are small and pale. For macrocytic anemia, elevated MCH, with normal or high MCHC, supports a diagnosis of megaloblastic anemia, typically due to folate or B12 deficiencies. These measurements provide greater accuracy by confirming the specific type of anemia, guiding decisions about nutrient supplementation [18].

4. Analyzing Red Cell Distribution Width (RDW): RDW assesses the variability in RBC size, with elevated RDW suggesting mixed anemia or ongoing changes in RBC production. For instance, a high RDW with low MCV points to iron deficiency anemia, where RBCs vary in size as iron stores fluctuate. In cases where high RDW and high MCV are observed, a folate or B12 deficiency is likely, as these deficiencies result in both large and variably sized RBCs. RDW is valuable in differentiating complex cases or mixed deficiencies, particularly in pregnant women who may have multiple concurrent deficiencies [19].

5. Combining Indices for Differential Diagnosis: By combining these red cell indices, healthcare providers can achieve a more precise diagnosis. For example, low MCV, low MCH, and high RDW are strongly indicative of iron deficiency anemia, while high MCV, high MCH, and high RDW are consistent with megaloblastic anemia from folate or B12 deficiency. Normocytic anemia with normal RDW can indicate anemia of chronic disease or hemolytic anemia, particularly if other tests, such as reticulocyte count and serum ferritin, support these findings [20].

6. Monitoring Treatment Response Using Red Cell Indices: After diagnosis, red cell indices are valuable for monitoring response to treatment. Regular assessments of hemoglobin, MCV, MCH, and RDW help clinicians track improvements and ensure the effectiveness of interventions, such as iron or folate supplementation. For instance, rising MCV and MCH after iron therapy suggest red cell recovery in iron deficiency anemia, while stabilization of hemoglobin and RDW indicates effective control of the anemia. This monitoring approach is particularly important in pregnancy, where maintaining appropriate hemoglobin levels and RBC health is critical for maternal and fetal well-being [21].

Monitoring Anemia Progression and Treatment in Pregnancy

Monitoring anemia during pregnancy is essential to ensure that both mother and fetus remain healthy and to minimize complications associated with untreated or poorly managed anemia. The progression and response to treatment can be effectively tracked through regular assessments of hemoglobin levels, red cell indices, iron stores, and other biomarkers. Effective monitoring allows for timely adjustments to treatment, enhancing maternal health and improving fetal outcomes. Here's a structured approach to monitoring anemia progression and response to treatment in pregnant women.

1. Baseline Assessment and Follow-Up Intervals: The monitoring process begins with an initial assessment of hemoglobin levels, red cell indices (MCV, MCH, MCHC, and RDW), and serum ferritin to establish a baseline. This first check generally occurs during the first trimester or at the first prenatal visit. For pregnant women diagnosed with anemia, follow-up intervals are typically every four to six weeks to monitor treatment efficacy. However, in severe cases or if the anemia is unresponsive to treatment, more frequent monitoring may be required to ensure adequate progress [22].

2. Tracking Hemoglobin and Hematocrit Levels: Hemoglobin and hematocrit levels are the primary indicators for evaluating anemia severity and response to treatment. Successful treatment should result in a gradual increase in hemoglobin levels, with a target of at least 10 g/dL by the second trimester and 11 g/dL by the third trimester. A rise in hemoglobin of 1 g/dL over two to four weeks is considered a positive response to iron supplementation or other specific therapies. If there is no significant improvement, alternative diagnoses or additional treatments, such as intravenous iron or folic acid, may be considered [23].

3. Monitoring Red Cell Indices for Treatment Response: Red cell indices provide valuable insights into the effectiveness of treatment. For instance, in iron deficiency anemia, the Mean Corpuscular Volume (MCV) and mean Corpuscular Hemoglobin (MCH) should gradually increase, reflecting improved RBC size and hemoglobin content as iron stores are replenished. Red cell Distribution Width (RDW) may remain elevated initially as new cells of varying sizes enter circulation but should normalize as the body's response to treatment stabilizes. A lack of expected changes in these indices may indicate noncompliance, malabsorption, or an incorrect diagnosis [24].

4. Assessing Iron Stores through Serum Ferritin and Transferrin Saturation: Serum ferritin, a marker of iron stores, is valuable in assessing iron levels in the body and monitoring replenishment in cases of iron deficiency anemia. A gradual rise in ferritin levels indicates successful iron supplementation. However, ferritin levels may be temporarily elevated in inflammatory conditions, which must be considered when interpreting results. Transferrin saturation can also be useful, as it reflects iron transport efficiency and bioavailability. Low transferrin saturation alongside low ferritin typically confirms iron deficiency, while normalization of both values indicates treatment success [25].

5. Detecting Side Effects and Adjusting Treatment: Monitoring also includes vigilance for side effects associated with

common anemia treatments. Iron supplementation, for example, can cause gastrointestinal issues such as constipation, nausea, or vomiting, which may lead to treatment noncompliance. In cases of folate or vitamin B12 supplementation, adverse reactions are rare but can include mild skin rashes or other minor effects. Healthcare providers may need to adjust the dose, switch to alternative formulations, or explore parenteral iron therapy if oral iron is poorly tolerated [26].

6. Postpartum Follow-Up: After delivery, continued monitoring of hemoglobin and iron levels is often necessary to assess recovery from pregnancy-associated anemia. The postpartum period demands careful observation to ensure that iron stores are adequately restored, especially in women who experienced severe anemia during pregnancy. Supplementation may continue for a few months postpartum, and follow-up blood tests help confirm that hemoglobin and ferritin levels have normalized.

Clinical Implications and Recommendations

The management of anemia in pregnancy carries significant clinical implications, as untreated or poorly controlled anemia can lead to adverse outcomes for both the mother and fetus. These include risks of preterm birth, low birth weight, postpartum hemorrhage, and increased maternal mortality. Given these potential consequences, a proactive approach to diagnosis, monitoring, and treatment of anemia in pregnancy is essential. Clinical guidelines and recommendations can ensure standardized care and optimize maternal-fetal health outcomes.

1. Early Screening and Risk Assessment: Routine screening for anemia in early pregnancy is crucial, as it enables prompt detection and classification of anemia types, allowing clinicians to implement appropriate treatments before complications arise. Early screening should include a complete blood count (CBC) with red cell indices, serum ferritin levels, and additional diagnostic tests as needed based on patient risk factors. Women at higher risk of anemia, such as those with multiple pregnancies, low socioeconomic status, or a history of nutritional deficiencies, should be closely monitored from the onset of pregnancy.

2. Tailored Treatment Based on Anemia Type: Effective management depends on accurately diagnosing the type of anemia and administering treatment tailored to its specific etiology. For instance, iron supplementation remains the cornerstone for treating iron deficiency anemia, the most common type in pregnancy, whereas folate or vitamin B12 supplements are essential for addressing megaloblastic anemia. The use of red cell indices to distinguish between microcytic, macrocytic, and normocytic anemia ensures that treatment is both targeted and efficient, reducing the risk of adverse effects associated with inappropriate therapies [25].

3. Nutritional Counseling and Supplementation: Nutritional counseling is an integral part of anemia management in pregnancy. Healthcare providers should educate pregnant women on the importance of a balanced diet rich in iron, folate, and vitamin B12 to prevent or mitigate anemia. Iron-rich foods, including lean meats, leafy greens, and fortified cereals, alongside vitamin C-rich foods to enhance absorption, are beneficial dietary recommendations. For women with confirmed anemia, daily iron and folic acid supplementation is recommended, starting as early as possible and

continuing through the postpartum period to replenish iron stores and support recovery [26].

4. Regular Monitoring and Follow-Up Care: Continuous monitoring using red cell indices, hemoglobin levels, and serum ferritin is essential for tracking the progression of anemia and the effectiveness of treatment. Follow-up testing should be scheduled at regular intervals throughout pregnancy, and adjustments to treatment should be made if hemoglobin and red cell indices do not show expected improvements. Consistent follow-up also allows clinicians to detect treatment-related side effects early, addressing issues such as gastrointestinal intolerance to iron supplements by recommending alternative formulations or methods of administration.

5. Consideration of Non-Dietary Causes: While nutritional deficiencies are the primary causes of anemia in pregnancy, other etiologies such as chronic diseases, hemoglobinopathies, and gastrointestinal malabsorption must be considered in cases unresponsive to standard supplementation. Identifying non-dietary causes allows for comprehensive and individualized management, potentially involving interdisciplinary care with gastroenterologists or hematologists when complex conditions are present. This approach is particularly important for ensuring that anemia refractory to conventional treatment does not compromise maternal and fetal health [26].

6. Guidelines for Postpartum Management: Postpartum anemia is common and can impact maternal recovery and the ability to care for the newborn. Clinical guidelines recommend that women with pregnancy-related anemia continue with iron and folate supplementation for at least three months postpartum to restore depleted iron stores. Monitoring hemoglobin and ferritin levels in the postpartum period ensures that maternal health is fully supported, preventing long-term effects of anemia and promoting optimal recovery.

Conclusion

Anemia in pregnancy is a prevalent condition with potentially serious implications for maternal and fetal health. This review highlights the critical role of red cell indices—MCV, MCH, MCHC, and RDW—in effectively diagnosing, categorizing, and monitoring anemia during pregnancy. Early screening and consistent use of red cell indices enable healthcare providers to identify anemia types accurately, allowing for targeted interventions that address underlying causes such as iron, folate, or vitamin B12 deficiencies. Through tailored treatment and regular monitoring, particularly of hemoglobin levels and iron stores, clinicians can effectively manage anemia, reducing risks of complications such as preterm birth, low birth weight, and maternal morbidity.

Incorporating a structured diagnostic approach that prioritizes personalized treatment is essential for optimizing maternal-fetal health outcomes. Nutritional counseling, supplementation, and dietary guidance further enhance the management strategy, equipping pregnant women with tools to maintain adequate iron and nutrient levels. Postpartum follow-up ensures recovery and minimizes the lingering effects of pregnancy-related anemia, supporting long-term maternal health and well-being.

References

- Owais A, Merritt C, Lee C, Bhutta ZA. Anemia among women of reproductive age: an overview of global burden, trends, determinants, and drivers of progress in low-and middle-income countries. *Nutrients*. 2021; 13: 2745.
- World Health Organization. Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia. 2008.
- Agreen FC, Obeagu EI. Anaemia among pregnant women: A review of African pregnant teenagers. *Journal of Public Health and Nutrition*. 2023; 6: 138.
- Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. Evaluation of protein C, protein S and fibrinogen of pregnant women with malaria in Owerri metropolis. *Madonna University journal of Medicine and Health Sciences*. 2022; 2: 1-9.
- Means RT. Iron deficiency and iron deficiency anemia: implications and impact in pregnancy, fetal development, and early childhood parameters. *Nutrients*. 2020; 12: 447.
- Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, Okpala PU, Agu CC. Assessment of Haematological Changes in Pregnant Women of Ido, Ondo State, Nigeria. *J Res Med Dent Sci*. 2021; 9: 145-8.
- Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*. 2024; 2: 38-58.
- Sapehia D, Mahajan A, Srinivasan R, Kaur J. Pre-natal dietary imbalance of folic acid and vitamin B12 deficiency adversely impacts placental development and fetal growth. *Placenta*. 2023; 132: 44-54.
- Obeagu EI, Obeagu GU. Sickle cell anaemia in pregnancy: a review. *International Research in Medical and Health Sciences*. 2023; 6: 10-3.
- Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. *Elite Journal of Haematology*. 2024; 2: 67-80.
- Obeagu EI, Ezimah AC, Obeagu GU. Erythropoietin in the anaemias of pregnancy: a review. *Int J Curr Res Chem Pharm Sci*. 2016; 3: 10-8.
- Muñoz M, Peña-Rosas JP, Robinson S, Milman N, Holzgreve W, Breymann C, et al. Patient blood management in obstetrics: management of anaemia and haematonic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. *Transfusion medicine*. 2018; 28: 22-39.
- Breymann C. Iron deficiency anemia in pregnancy. In *Seminars in hematology*. WB Saunders. 2015; 52: 339-347.
- Green R, Mitra AD. Megaloblastic anemias: nutritional and other causes. *Medical Clinics*. 2017; 101: 297-317.
- Rashid S, Meier V, Patrick H. Review of Vitamin B12 deficiency in pregnancy: a diagnosis not to miss as veganism and vegetarianism become more prevalent. *European journal of haematology*. 2021; 106: 450-455.
- Jagnade RS, Bharat R, Singh P. Association Between Systemically Healthy Chronic Periodontitis Pregnant Female Subjects and Anemia of Chronic Diseases: A Clinical Study. *Journal of Advanced Medical and Dental Sciences Research*. 2018; 6: 88-95.
- BarreraReyes PK, Tejero ME. Genetic variation influencing hemoglobin levels and risk for anemia across populations. *Annals of the New York Academy of Sciences*. 2019; 1450: 32-46.
- Guyatt GH, Oxman AD, Ali M, Willan A, McIlroy W, Patterson C. Laboratory diagnosis of iron-deficiency anemia: an overview. *Journal of general internal medicine*. 1992; 7: 145-53.
- Eweis M, Farid EZ, El-Malky N, Abdel-Rasheed M, Salem S, Shawky S. Prevalence and determinants of anemia during the third trimester of pregnancy. *Clinical Nutrition ESPEN*. 2021; 44: 194-199.
- Agbozo F, Abubakari A, Der J, Jahn A. Maternal dietary intakes, red blood cell indices and risk for anemia in the first, second and third trimesters of pregnancy and at predelivery. *Nutrients*. 2020; 12: 777.
- Siteti MC, Namasaka SD, Ariya OP, Injete SD, Wanyonyi WA. Anaemia in pregnancy: Prevalence and possible risk factors in Kakamega County, Kenya. *Science journal of public health*. 2014; 2: 216-222.

22. Kumar SB, Arnipalli SR, Mehta P, Carrau S, Ziouzenkova O. Iron deficiency anemia: efficacy and limitations of nutritional and comprehensive mitigation strategies. *Nutrients*. 2022; 14: 2976.
23. Pai RD, Chong YS, Clemente-Chua LR, Irwindia R, Huynh TN, Wibowo N, et al. Prevention and management of iron deficiency/iron-deficiency anemia in women: an Asian expert consensus. *Nutrients*. 2023; 15: 3125.
24. Muñoz M, Peña-Rosas JP, Robinson S, Milman N, Holzgreve W, Breymann C, et al. Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement. *Transfusion medicine*. 2018; 28: 22-39.
25. Shi H, Chen L, Wang Y, Sun M, Guo Y, Ma S, et al. Severity of anemia during pregnancy and adverse maternal and fetal outcomes. *JAMA network open*. 2022; 5: e2147046.
26. World Health Organization. Guideline: daily iron and folic acid supplementation in pregnant women. World Health Organization. 2012.